About Lexeo Therapeutics Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://www.lexeotx.com/
Frequently Asked Questions
What is the 52-week range for LXEO?
The 52-week high is $10.99 and the 52-week low is $2.98.
What is the P/E ratio for LXEO?
The P/E ratio data is currently unavailable.
What is the dividend yield for LXEO?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -41.85%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -11991.84%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 2.94.
Analyst Recommendation Trends
Wall Street analyst consensus for LXEO over the last few months:
Latest LXEO News
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control cohort from UNIFAI natural history study Presentation will include new mFARS subscore analyses providing additional insight into neurologic outcomes following LX2006 treatment NEW YORK, Oct. 01, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on resha
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, access to TfR1 CapX™ for a program designed to treat Friedreich ataxia. Apertura's TfR1 CapX is an intravenously delivered AAV capsid designed to target human transferrin receptor 1 (hTfR1) and cross the blood-brain barrier.
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced that the Company will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on September 30, 2026 at 9:00am ET. The event will be webcast live under the Events & Presentations tab in the Investors section of the Company’s website. A replay of the webcast will be available on
Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript
Lexeo Therapeutics, Inc. (LXEO) M&A Call September 22, 2026 8:00 AM EDTCompany ParticipantsAshley Kaplowitz - Head of Capital MarketsR.
Lexeo Therapeutics, Inc. (LXEO) Mantle Therapeutics Inc. - M&A Call - Slideshow
2026-09-22. The following slide deck was published by Lexeo Therapeutics, Inc.
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following treatment with LX2006 and explore cerebellar targeting to optimize outcomes in FA associated neurological disease SUNRISE-FA 2 pivotal study continues enrollment and remains the company’s top priority development program; topline data on track for 2H 2027 Disciplined capital allocation supports these
Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. stock futures were mixed. Ericsson fell 4.3% after a Morgan Stanley downgrade; Quest Diagnostics, Rambus and others also declined premarket.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-24 | Bhalla Narinder Pal | +54,750 | - | - |
| 2026-09-24 | Tamayo Louis Edward | +54,750 | - | - |
| 2026-09-24 | Otero Jose Manuel | +54,750 | - | - |
| 2026-09-24 | Townsend Richard Nolan | +145,500 | - | - |
| 2026-09-14 | Bhalla Narinder Pal | +2,714 | $3.579 | $9,713 |
| 2026-09-14 | Otero Jose Manuel | +2,110 | $2.644 | $5,579 |
| 2026-09-14 | Townsend Richard Nolan | +2,306 | $2.644 | $6,097 |
| 2026-08-18 | Tamayo Louis Edward | -4,117 | $4.9071 | $20,203 |
| 2026-08-18 | Otero Jose Manuel | -1,304 | $4.9571 | $6,464 |
| 2026-08-18 | Townsend Richard Nolan | -3,345 | $4.9512 | $16,562 |
| 2026-07-01 | Bhalla Narinder Pal | -22,306 | $4.42 | $98,593 |
| 2026-07-01 | Tamayo Louis Edward | -4,641 | $4.49 | $20,838 |
| 2026-07-01 | Otero Jose Manuel | -4,666 | $4.48 | $20,904 |
| 2026-07-01 | Townsend Richard Nolan | -25,947 | $4.48 | $116,243 |
| 2026-06-29 | Bhalla Narinder Pal | +55,000 | - | - |
| 2026-06-29 | Tamayo Louis Edward | +12,000 | - | - |
| 2026-06-29 | Otero Jose Manuel | +12,060 | - | - |
| 2026-06-29 | Townsend Richard Nolan | +67,000 | - | - |
| 2026-04-28 | Sepp-Lorenzino Laura | +50,000 | - | - |
| 2026-04-06 | Townsend Richard Nolan | -55,000 | $5.6934 | $313,137 |
| 2026-03-13 | Otero Jose Manuel | +5,930 | $2.644 | $15,679 |
| 2026-03-13 | Townsend Richard Nolan | +2,623 | $2.644 | $6,935 |
| 2026-02-18 | Otero Jose Manuel | -3,016 | $6.3972 | $19,294 |
| 2026-02-18 | Townsend Richard Nolan | -10,173 | $6.382 | $64,924 |
| 2026-02-13 | Bhalla Narinder Pal | +297,000 | - | - |
| 2026-02-13 | Bhalla Narinder Pal | +49,500 | - | - |
| 2026-02-04 | Tamayo Louis Edward | +226,665 | - | - |
| 2026-02-04 | Tamayo Louis Edward | +44,665 | - | - |
| 2026-02-04 | Otero Jose Manuel | +260,000 | - | - |
| 2026-02-04 | Otero Jose Manuel | +65,000 | - | - |
| 2026-02-04 | Townsend Richard Nolan | +646,665 | - | - |
| 2026-02-04 | Townsend Richard Nolan | +161,665 | - | - |
| 2025-11-18 | Otero Jose Manuel | -721 | $9.27 | $6,684 |
| 2025-11-18 | See Tai Sandi | -386 | $9.27 | $3,578 |
| 2025-11-18 | Townsend Richard Nolan | -1,127 | $9.27 | $10,447 |
| 2025-11-18 | Robertson Jenny | -549 | $9.27 | $5,089 |
| 2025-11-18 | Adler Eric | -615 | $9.27 | $5,701 |
| 2025-10-17 | Otero Jose Manuel | -24 | $9.561 | $229 |
| 2025-10-17 | Otero Jose Manuel | -2,091 | $8.935 | $18,683 |
| 2025-10-17 | See Tai Sandi | -44 | $9.561 | $421 |
| 2025-10-17 | See Tai Sandi | -3,844 | $8.935 | $34,346 |
| 2025-10-17 | Townsend Richard Nolan | -148 | $9.561 | $1,415 |
| 2025-10-17 | Townsend Richard Nolan | -12,985 | $8.935 | $116,021 |
| 2025-10-17 | Robertson Jenny | -40 | $9.561 | $382 |
| 2025-10-17 | Robertson Jenny | -3,486 | $8.935 | $31,147 |
| 2025-10-17 | Adler Eric | -38 | $9.561 | $363 |
| 2025-10-17 | Adler Eric | -3,344 | $8.935 | $29,879 |
| 2025-10-15 | Otero Jose Manuel | +5,940 | - | - |
| 2025-10-15 | See Tai Sandi | +10,890 | - | - |
| 2025-10-15 | Townsend Richard Nolan | +33,000 | - | - |
| 2025-10-15 | Robertson Jenny | +9,900 | - | - |
| 2025-10-15 | Adler Eric | +9,570 | - | - |